



# Correction to: Ceftriaxone Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

Susanna Esposito<sup>1</sup> · Timothy J. Carrothers<sup>2</sup> · Todd Riccobene<sup>2</sup> · Gregory G. Stone<sup>3</sup> · Michal Kantecki<sup>4</sup>

Published online: 7 October 2021  
© The Author(s) 2021

## Correction to: Pediatric Drugs

<https://doi.org/10.1007/s40272-021-00468-w>

The article “Ceftriaxone Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia”, written by Susanna Esposito, Timothy J. Carrothers, Todd Riccobene, Gregory G. Stone and Michal Kantecki was originally published electronically on the publisher’s internet portal on 31st August 2021 without open access.

With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 20th September 2021 to © The Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to

obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

---

The original article can be found online at <https://doi.org/10.1007/s40272-021-00468-w>.

✉ Susanna Esposito  
susannamariaroberta.esposito@unipr.it

<sup>1</sup> Pediatric Clinic, Pietro Barilla Children’s Hospital, University of Parma, Building 15, Via Gramsci 14, 43126 Parma, Italy

<sup>2</sup> AbbVie, Madison, NJ, USA

<sup>3</sup> Pfizer, Groton, CT, USA

<sup>4</sup> Pfizer, Paris, France